MHRA disrupts second manufacturing site near Sleaford and Grantham

In February 2026, MHRA officers raided premises near Sleaford and Grantham believed to have been used for manufacturing and distributing unlicensed weight-loss medicines, including retatrutide and tirzepatide — the second identified UK operation in this category, four months after the Northampton factory.

Why a second site matters

One raid could be treated as an isolated incident. A second, geographically separate operation confirms this is an active pattern of unlicensed manufacturing and distribution, not a one-off — and it's the reason this page tracks these actions individually rather than treating the first raid as a closed story.

What this means for the "is it legal" question

Nothing about this changes retatrutide's UK status: it remains unlicensed, and buying it from any UK source remains a criminal offence under the Human Medicines Regulations 2012 for the seller, and a real safety risk for the buyer, regardless of how the product is labelled. See the full UK status page for the complete regulatory picture.